These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11204595)

  • 1. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.
    Sandberg H; Almstedt A; Brandt J; Gray E; Holmquist L; Oswaldsson U; Sebring S; Mikaelsson M
    Thromb Haemost; 2001 Jan; 85(1):93-100. PubMed ID: 11204595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol.
    Röstin J; Smeds AL; Akerblom E
    Bioconjug Chem; 2000; 11(3):387-96. PubMed ID: 10821655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.
    Lind P; Larsson K; Spira J; Sydow-Bäckman M; Almstedt A; Gray E; Sandberg H
    Eur J Biochem; 1995 Aug; 232(1):19-27. PubMed ID: 7556150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
    Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
    J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.
    Donath MJ; de Laaf RT; Biessels PT; Lenting PJ; van de Loo JW; van Mourik JA; Voorberg J; Mertens K
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):49-55. PubMed ID: 7492334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid residues 721-729 are required for full factor VIII activity.
    Kjalke M; Heding A; Talbo G; Persson E; Thomsen J; Ezban M
    Eur J Biochem; 1995 Dec; 234(3):773-9. PubMed ID: 8575434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
    Saenko EL; Scandella D
    J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.
    Layet S; Girma JP; Obert B; Peynaud-Debayle E; Bihoreau N; Meyer D
    Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):129-37. PubMed ID: 1531749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of von Willebrand factor on activation of factor VIII by factor Xa.
    Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ
    Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of coagulation factor VIII with members of the low-density lipoprotein receptor family follows common mechanism and involves consensus residues within the A2 binding site 484-509.
    Ananyeva NM; Makogonenko YM; Sarafanov AG; Pechik IV; Gorlatova N; Radtke KP; Shima M; Saenko EL
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):543-55. PubMed ID: 18685438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors.
    D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L
    Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
    Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
    Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.
    Lewis DA; Pound ML; Ortel TL
    Thromb Haemost; 2003 May; 89(5):795-802. PubMed ID: 12719775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK; Lee JM; Byun TH; Park SY; Kim YH
    Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
    Li X; Gabriel DA
    Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs.
    Gilbert GE; Kaufman RJ; Arena AA; Miao H; Pipe SW
    J Biol Chem; 2002 Feb; 277(8):6374-81. PubMed ID: 11698391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
    Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
    Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
    Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.